We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has announced that it will not impose restrictions on “IRB shopping,” a practice in which clinical trial sponsors submit trial research to institutional review boards (IRBs) that they feel are likely to approve the trial. The agency’s statement was published in the Jan. 17 Federal Register.